Resource Logo
AIDS Weekly Plus

HIV/AIDS: Indinavir/ritonavir less effective than lopinavir/ritonavir as first-line HAART






 

-- Indinavir/ritonavir less effective than lopinavir/ritonavir as first-line HAART in HIV-1-infected patients.

Immunovirological "outcomes and toxicities of HAART regimens, including Lopinavir (LPV)/ritonavir (r) and indinavir (IDV)/r," were compared in antiretroviral naive HIV-1 patients. Fifty-five and 52 patients, respectively, were selected to start LPV/r or IDV/r as first-line HAART, according to research in Italy.

"Immunovirological and metabolic parameters were recorded at baseline and every 3 months as were side effects, AIDS-defining events and deaths. Demographic characteristics and NRTIs included in the regimens were comparable," wrote M. Bongiovanni and colleagues.

"Both groups reached undetectable HIV-RNA plasma viremia" by the third month, which was maintained during follow-up. However, patients receiving IDV/r were less likely "to obtain virological success (RH: 0.46). Patients receiving IDV/r showed a greater increase of total cholesterol (P = 0.01). Three patients on LPV/r and 21 on IDV/r discontinued the drug for toxicity, leading to an 8.40 higher risk of discontinuation in the latter group," M. Bongiovanni and colleagues reported.

Results indicate that IDV/r is "less effective and more toxic than LPV/RTV as first-line HAART," concluded the investigators.

Bongiovanni and colleagues published the results of their research in Antiviral Research (Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects. Antiviral Res. 2004 Apr;62(1):53-6.

For additional information, contact M. Bongiovanni, University Milan, L Sacco Hospital Vialba, Institute Infection Diseases & Trop Med, Via GB Grassi 74, I-20157 Milan, Italy.

The publisher of the journal Antiviral Research can be contacted at: Elsevier Science BV, PO Box 211, 1000 AE Amsterdam, Netherlands.

The information in this article comes under the major subject areas of AIDS and HIV, Antiretroviral, Pharmaceutical & Drug Development and Toxicity.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Bongiovanni M, Bini T, Chiesa E, et al., "Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects", Antiviral Res. 2004 Apr;62(1):53-6

PubMED Related articles Search



 


Copyright © 2004 -AIDS Weekly Plus, Publisher. All rights reserved to Charles Henderson, Publisher. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633- 4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX:(205) 995-1588 Visit AIDS WEEKLY PLUS.



Information in this article was accurate in May 24, 2004. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.